The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.

"Competing interests KS receives grant funding from the DFCI/Novartis Drug Discovery Program and from KronosBio, is a member of the SAB and has stock options with Auron Therapeutics and has consulted for AstraZeneca on topics unrelated to this work. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck, Vir), and is a director of Addgene, Inc."

"CS was supported by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG], (SCHN 1622/1-1)) and a Helen Gurley Brown Fellowship and CS and KS with funding from “The Selig Family Fund for Pediatric Cancer Research”. This work was also supported by the National Cancer Institute R35 CA210030, R35 CA283977 (KS), P50 CA206963 (KS) and K99 CA263161 (SL). SL was a Fellow of the Leukemia and Lymphoma Society."